Sitagliptin INN (immediate release) +Metformin HCl USP (extended release)
Composition: Sliptin-M ER 500: Sitagliptin INN Immediate Release 50 mg + Metformin Hydrochloride USP Extended Release 500 mg Tablet.
Sliptin-M ER 1000: Sitagliptin INN Immediate Release 50 mg + Metformin Hydrochloride USP Extended Release 1000 mg Tablet.
Indications: Sitagliptin and Metformin ER is a dipeptidyl peptidase-4 (DPP-4) inhibitor and biguanide combination product indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both sitagliptin and metformin is appropriate.
Dosage & Administration: May adjust the dosing based on effectiveness and tolerability while not exceeding the maximum recommended daily dose of 100 mg Sitagliptin and 2000 mg Metformin Extended Release. Administer once daily with a meal preferably in the evening. Gradually escalate the dose to reduce the gastrointestinal side effects due to Metformin. Maintain the same total daily dose of Sitagliptin & Metformin when changing between Sitagliptin and Metformin ER, without exceeding the maximum recommended daily dose of 2000 mg Metformin extended release. Swallow whole. Never split, crush or chwe. Or, asdirected by the registered physician.
Use in Pregnency & Lactation: Sliptin-M ER has been assigned to pregnancy category-B by the FDA. There are no controlled data in women pregnancy. It can be used in pregnancy if potential benefits outweigh the risk or as directed by the registered physician. Sliptin-M ER is likely to be excreted into the breast milk. A decision should be made whether to discontiune nursing or to discontinue the drug, taking into account the benefit of the drug to the mother.
Packing: Sliptin-M 1000 ER : Each box contains 2x7's tablets in blister pack.
Sliptin-M 500 ER : Each box contains 2x7's tablets in blister pack.
